Citation: Yan SU, Meng-Meng WANG, Hong-Ke LIU, Zhi SU. Synthesis and Antitumor Properties of Temozolomide-Based Platinum(Ⅳ) Complexes[J]. Chinese Journal of Inorganic Chemistry, ;2022, 38(3): 430-440. doi: 10.11862/CJIC.2022.044 shu

Synthesis and Antitumor Properties of Temozolomide-Based Platinum(Ⅳ) Complexes

School of Chemistry and Materials Science, Nanjing Normal University, Nanjing 210023, China

Corresponding author: Hong-Ke LIU, liuhongke@njnu.edu.cn Zhi SU, zhisu@njnu.edu.cn
Received Date: 9 September 2021
Revised Date: 14 December 2021

Figures(9)

Temozolomide is the first-line anticancer drug for the clinical treatment of glioblastoma. In this work, temozolomide was chemically modified and introduced into the platinum(Ⅳ) complex. Two new Pt(Ⅳ) complexes P1T and P2T were successfully synthesized and characterized by ¹H NMR and ¹³C NMR. The results show that both complexes had good lipid solubility with a fast hydrolysis rate. The anticancer activity and the mechanism of P1T and P2T were investigated with the MTT assay, flow cytometry, confocal imaging, and western blot. The results demonstrate that complexes P1T and P2T owned high cytotoxicity to glioma cell line A261, but low toxicity to normal nerve cell HT-22, indicating good cancer cell selectivity. Flow cytometry reveals that complexes P1T and P2T arrest the cell cycle in the G2/M phase, leading to DNA damage and ultimately inducing tumor cell apoptosis.
- temozolomide,
- platinum complex,
- glioblastoma,
- anticancer drug
1. [1]
  Louis D N, Perry A, Reifenberger G, Deimling A, Figarella-Branger D, Cavenee W K, Ohgaki H, Wiestler O D, Kleihues P, Ellison D W. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A Summary[J]. Acta Neuropathol., 2016,131(6):803-820. doi: 10.1007/s00401-016-1545-1
2. [2]
  Giese A, Bjerkvig R, Berens M E, Westphal M. Cost of Migration: Invasion of Malignant Gliomas and Implications for Treatment[J]. J. Clin. Oncol., 2003,21(8):1624-1636. doi: 10.1200/JCO.2003.05.063
3. [3]
  Affronti M L, Heery C R, Herndon J E, Rich J N, Reardon D A, Desjardins A, Vredenburgh J J, Friedman A H, Bigner D D, Friedman H S. Overall Survival of Newly Diagnosed Glioblastoma Patients Receiving Carmustine Wafers Followed by Radiation and Concurrent Temozolomide plus Rotational Multiagent Chemotherapy[J]. Cancer, 2009,115(15):3501-3511. doi: 10.1002/cncr.24398
4. [4]
  de Souza R M, Shaweis H, Han C, Sivasubramaniam V, Brazil L, Beaney R, Sadler G, Al-Sarraj S, Hampton T, Logan J, Hurwitz V, Bhangoo R, Gullan R, Ashkan K. Erratum: Has the Survival of Patients with Glioblastoma Changed over the Years?[J]. Br. J. Cancer, 2016,114(2):146-150. doi: 10.1038/bjc.2015.421
5. [5]
  Stupp R, Taillibert S, Kanner A, Read W, Steinberg D M, Lhermitte B, Toms S, Idbaih A, Ahluwalia M S, Fink K, Di Meco F, Lieberman F, Zhu J J, Stragliotto G, Tran D D, Brem S, Hottinger A F, Kirson E D, Lavy-Shahaf G, Weinberg U, Kim C Y, Paek S H, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi M E, Ram Z. Effect of Tumor-Treating Fields plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial[J]. JAMA - J. Am. Med. Assoc., 2017,318(23):2306-2316. doi: 10.1001/jama.2017.18718
6. [6]
  Furnari F B, Fenton T, Bachoo R M, Mukasa A, Stommel J M, Stegh A, Hahn W C, Ligon K L, Louis D N, Brennan C, Chin L, DePinho R A, Cavenee W K. Malignant Astrocytic Glioma: Genetics, Biology, and Paths to Treatment[J]. Genes Dev., 2007,21(21):2683-2710. doi: 10.1101/gad.1596707
7. [7]
  Fan C H, Liu W L, Cao H, Wen C, Chen L, Jiang G. O⁶-Methylgua-nine DNA Methyltransferase as a Promising Target for the Treatment of Temozolomide-Resistant Gliomas[J]. Cell Death Dis., 2013,4(10)e876. doi: 10.1038/cddis.2013.388
8. [8]
  Hirose Y, Berger M S, Pieper R O. p53 Effects both the Duration of G₂ & M Arrest and the Fate of Temozolomide-Treated Human Glioblas- toma Cells[J]. Cancer Res., 2001,61(5):1957-1963.
9. [9]
  Friedman H S, Kerby T, Calvert H. Temozolomide and Treatment of Malignant Glioma[J]. Clin. Cancer Res., 2000,6(7):2585-2597.
10. [10]
  Gerson S L. MGMT: Its Role in Cancer Aetiology and Cancer Thera-peutics[J]. Nat. Rev. Cancer, 2004,4(4):296-307. doi: 10.1038/nrc1319
11. [11]
  Lee S Y. Temozolomide Resistance in Glioblastoma Multiforme[J]. Genes Dis., 2016,3(3):198-210. doi: 10.1016/j.gendis.2016.04.007
12. [12]
  Stupp R, Mason W P, van den Bent M J, Weller M, Fisher B, Taphoorn M J B, Belanger K, Brandes A A, Marosi C, Bogdahn U, Curschmann J, Janzer R C, Ludwin S K, Gorlia T, Allgeier A, Lacombe D, Cairncross J G, Eisenhauer E, Mirimanoff R O. Radio-therapy plus Concomitant and Adjuvant Temozolomide for Glioblas-toma[J]. N. Engl. J. Med., 2005,352(10):987-996. doi: 10.1056/NEJMoa043330
13. [13]
  Stupp R, Hegi M E, Mason W P, Bent M J, Taphoorn M J B, Janzer R C, Ludwin S K, Allgeier A, Fisher B, Belanger K, Hau P, Brandes A A, Gijtenbeek J, Marosi C, Vecht C J, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross J G, Mirimanoff R O. Effects of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy Alone on Survival in Glioblastoma in a Randomised Phase Ⅲ Study: 5-Year Analysis of the EORTC-NCIC Trial[J]. Lancet Oncol., 2009,10(5):459-466. doi: 10.1016/S1470-2045(09)70025-7
14. [14]
  Rosenberg B, Vancamp L, Trosko J E, Mansour V H. Platinum Com- pounds: A New Class of Potent Antitumour Agents[J]. Nature, 1969,222(5191):385-386. doi: 10.1038/222385a0
15. [15]
  Wang X H, Wang X Y, Jin S X, Muhammad N, Guo Z J. Stimuli-Responsive Therapeutic Metallodrugs[J]. Chem. Rev., 2019,119(2):1138-1192. doi: 10.1021/acs.chemrev.8b00209
16. [16]
  JIN S X, GUO Z J, WANG X Y. Antitumor Metal Complexes Target-ing Energy Metabolism[J]. Progress in Pharmaceutical Sciences, 2020,44(4):280-293.
17. [17]
  Klein A V, Hambley T W. Platinum Drug Distribution in Cancer Cells and Tumors[J]. Chem. Rev., 2009,109(10):4911-4920. doi: 10.1021/cr9001066
18. [18]
  Dilruba S, Kalayda G V. Platinum-Based Drugs: Past, Present and Future[J]. Cancer Chemother. Pharmacol., 2016,77(6):1103-1124. doi: 10.1007/s00280-016-2976-z
19. [19]
  Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G. Molecular Mechanisms of Cisplatin Resis-tance[J]. Oncogene, 2012,31(15):1869-1883. doi: 10.1038/onc.2011.384
20. [20]
  Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bel-lan A, Castedo M, Kroemer G. Systems Biology of Cisplatin Resis-tance: Past, Present and Future[J]. Cell Death Dis., 2014,5(5)e1257. doi: 10.1038/cddis.2013.428
21. [21]
  Wang X Y, Guo Z J. Targeting and Delivery of Platinum-Based Anti-cancer Drugs[J]. Chem. Soc. Rev., 2013,42(1):202-224. doi: 10.1039/C2CS35259A
22. [22]
  Oun R, Moussa Y E, Wheate N J. The Side Effects of Platinum-Based Chemotherapy Drugs: A Review for Chemists[J]. Dalton Trans., 2018,47(19):6645-6653. doi: 10.1039/C8DT00838H
23. [23]
  Karasawa T, Steyger P S. An Integrated View of Cisplatin-Induced Nephrotoxicity and Ototoxicity[J]. Toxicol. Lett., 2015,237(3):219-227. doi: 10.1016/j.toxlet.2015.06.012
24. [24]
  Johnstone T C, Suntharalingam K, Lippard S J. The Next Generation of Platinum Drugs: Targeted Pt Agents, Nanoparticle Delivery, and Pt Prodrugs[J]. Chem. Rev., 2016,116(5):3436-3486. doi: 10.1021/acs.chemrev.5b00597
25. [25]
  Wilson J J, Lippard S J. Synthetic Methods for the Preparation of Platinum Anticancer Complexes[J]. Chem. Rev., 2014,114(8):4470-4495. doi: 10.1021/cr4004314
26. [26]
  Hall M D, Hambley T W. Platinum Antitumour Compounds: Their Bioinorganic Chemistry[J]. Coord. Chem. Rev., 2002,232(1):49-67.
27. [27]
  Jin S X, Hao Y Y, Zhu Z Z, Muhammad N, Zhang Z Q, Wang K, Guo Y, Guo Z J, Wang X Y. Impact of Mitochondrion-Targeting Group on the Reactivity and Cytostatic Pathway of Platinum Complexes[J]. Inorg. Chem., 2018,57(17):11135-11145. doi: 10.1021/acs.inorgchem.8b01707
28. [28]
  Shi Y, Liu S A, Kerwood D J, Goodisman J, Dabrowiak J C. Pt Complexes as Prodrugs for Cisplatin[J]. J. Inorg. Biochem., 2012,107(1):6-14. doi: 10.1016/j.jinorgbio.2011.10.012
29. [29]
  Arrowsmith J, Jennings S A, Clark A S, Stevens M F G. Antitumor Imidazotetrazines. 41. Conjugation of the Antitumor Agents Mitozolo-mide and Temozolomide to Peptides and Lexitropsins Bearing DNA Major and Minor Groove-Binding Structural Motifs[J]. J. Med. Chem., 2002,45(25):5458-5470.
30. [30]
  Huang H Y, Yu B L, Zhang P Y, Huang J J, Chen Y, Gasser G, Ji L N, Chao H. Highly Charged Ruthenium Polypyridyl Complexes as Lysosome-Localized Photosensitizers for Two-Photon Photodynamic Therapy[J]. Angew. Chem. Int. Ed., 2015,54(47):14049-14052. doi: 10.1002/anie.201507800
31. [31]
  Huang H Y, Zhang P Y, Yu B L, Chen Y, Wang J Q, Ji L N, Chao H. Targeting Nucleus DNA with a Cyclometalated Dipyridophenazineru-thenium Complex[J]. J. Med. Chem., 2014,57(21):8971-8983. doi: 10.1021/jm501095r
32. [32]
  Oldfield S P, Hall M D, Platts J A. Calculation of Lipophilicity of a Large, Diverse Dataset of Anticancer Platinum Complexes and the Relation to Cellular Uptake[J]. J. Med. Chem., 2007,50(21):5227-5237. doi: 10.1021/jm0708275
33. [33]
  Bonner W M, Redon C E, Dickey J S, Nakamura A J, Sedelnikova O A, Solier S, Pommier Y. γH2AX and Cancer[J]. Nat. Rev. Cancer, 2008,8(12):957-967. doi: 10.1038/nrc2523
34. [34]
  Revet I, Feeney L, Bruguera S, Wilson W, Dong T K, Oh D H, Dankort D, Cleaver J E. Functional Relevance of the Histone γH2Ax in the Response to DNA Damaging Agents[J]. Proc. Natl. Acad. Sci. U. S. A., 2011,108(21):8663-8667. doi: 10.1073/pnas.1105866108
35. [35]
  Shieh S Y, Ikeda M, Taya Y, Prives C. DNA Damage-Induced Phos-phorylation of p53 Alleviates Inhibition by MDM2[J]. Cell, 1997,91(3):325-334. doi: 10.1016/S0092-8674(00)80416-X
36. [36]
  Wang D, Lippard S J. Cellular Processing of Platinum Anticancer Drugs[J]. Nat. Rev. Drug Discovery, 2005,4(4):307-320. doi: 10.1038/nrd1691
37. [37]
  Zhou Z J, Song J B, Nie L M, Chen X Y. Reactive Oxygen Species Generating Systems Meeting Challenges of Photodynamic Cancer Therapy[J]. Chem. Soc. Rev., 2016,45(23):6597-6626. doi: 10.1039/C6CS00271D
38. [38]
  WU J, TAO Q, GE C, XUE X L, QIAN Y, LIU H K. Synthesis and Antitumor Properties of Ruthenium-Arene Complexes Based on Nat-ural Product Perillol[J]. Chinese J. Inorg. Chem., 2020,36(7):1223-1232.
39. [39]
  Wang F X, Liang J H, Zhang H, Wang Z H, Wan Q, Tan C P, Ji L N, Mao Z W. Mitochondria-Accumulating Rhenium Tricarbonyl Com-plexes Induce Cell Death via Irreversible Oxidative Stress and Gluta-thione Metabolism Disturbance[J]. ACS Appl. Mater. Interfaces, 2019,11(14):13123-13133. doi: 10.1021/acsami.9b01057
40. [40]
  Carneiro B A, El-Deiry W S. Targeting Apoptosis in Cancer Therapy[J]. Nat. Rev. Clin. Oncol., 2020,17(7):395-417. doi: 10.1038/s41571-020-0341-y
1. [1]
  Ping Song , Nan Zhang , Jie Wang , Rui Yan , Zhiqiang Wang , Yingxue Jin . Experimental Teaching Design on Synthesis and Antitumor Activity Study of Cu-Pyropheophorbide-a Methyl Ester. University Chemistry, 2024, 39(6): 278-286. doi: 10.3866/PKU.DXHX202310087
2. [2]
  Yongpo Zhang , Xinfeng Li , Yafei Song , Mengyao Sun , Congcong Yin , Chunyan Gao , Jinzhong Zhao . Synthesis of Chlorine-Bridged Binuclear Cu(I) Complexes Based on Conjugation-Driven Cu(II) Oxidized Secondary Amines. University Chemistry, 2024, 39(5): 44-51. doi: 10.3866/PKU.DXHX202309092
3. [3]
  Zhilian Liu , Wengui Wang , Hongxiao Yang , Yu Cui , Shoufeng Wang . Ideological and Political Education Design for the Synthesis of Irinotecan Drug Intermediate 7-Ethyl Camptothecin. University Chemistry, 2024, 39(2): 89-93. doi: 10.3866/PKU.DXHX202306012
4. [4]
  Zhibei Qu , Changxin Wang , Lei Li , Jiaze Li , Jun Zhang . Organoid-on-a-Chip for Drug Screening and the Inherent Biochemistry Principles. University Chemistry, 2024, 39(7): 278-286. doi: 10.3866/PKU.DXHX202311039
5. [5]
  Chunmei GUO , Weihan YIN , Jingyi SHI , Jianhang ZHAO , Ying CHEN , Quli FAN . Facile construction and peroxidase-like activity of single-atom platinum nanozyme. Chinese Journal of Inorganic Chemistry, 2024, 40(9): 1633-1639. doi: 10.11862/CJIC.20240162
6. [6]
  Aidang Lu , Yunting Liu , Yanjun Jiang . Comprehensive Organic Chemistry Experiment: Synthesis and Characterization of Triazolopyrimidine Compounds. University Chemistry, 2024, 39(8): 241-246. doi: 10.3866/PKU.DXHX202401029
7. [7]
  Xiaowei TANG , Shiquan XIAO , Jingwen SUN , Yu ZHU , Xiaoting CHEN , Haiyan ZHANG . A zinc complex for the detection of anthrax biomarker. Chinese Journal of Inorganic Chemistry, 2024, 40(10): 1850-1860. doi: 10.11862/CJIC.20240173
8. [8]
  Ziheng Zhuang , Xiao Xu , Kin Shing Chan . Superdrugs for Superbugs. University Chemistry, 2024, 39(9): 128-133. doi: 10.3866/PKU.DXHX202309040
9. [9]
  Zhen Yao , Bing Lin , Youping Tian , Tao Li , Wenhui Zhang , Xiongwei Liu , Wude Yang . Visible-Light-Mediated One-Pot Synthesis of Secondary Amines and Mechanistic Exploration. University Chemistry, 2024, 39(5): 201-208. doi: 10.3866/PKU.DXHX202311033
10. [10]
  Qilu DU , Li ZHAO , Peng NIE , Bo XU . Synthesis and characterization of osmium-germyl complexes stabilized by triphenyl ligands. Chinese Journal of Inorganic Chemistry, 2024, 40(6): 1088-1094. doi: 10.11862/CJIC.20240006
11. [11]
  Haitang WANG , Yanni LING , Xiaqing MA , Yuxin CHEN , Rui ZHANG , Keyi WANG , Ying ZHANG , Wenmin WANG . Construction, crystal structures, and biological activities of two Ln^Ⅲ₃ complexes. Chinese Journal of Inorganic Chemistry, 2024, 40(8): 1474-1482. doi: 10.11862/CJIC.20240188
12. [12]
  Wei Li , Ze Chang , Meihui Yu , Ying Zhang . Curriculum Ideological and Political Design of Piezoelectricity Measurement Experiments of Coordination Compounds. University Chemistry, 2024, 39(2): 77-82. doi: 10.3866/PKU.DXHX202308004
13. [13]
  Ji Qi , Jianan Zhu , Yanxu Zhang , Jiahao Yang , Chunting Zhang . Visible Color Change of Copper (II) Complexes in Reversible SCSC Transformation: The Effect of Structure on Color. University Chemistry, 2024, 39(3): 43-57. doi: 10.3866/PKU.DXHX202307050
14. [14]
  Cunling Ye , Xitong Zhao , Hongfang Wang , Zhike Wang . A Formula for the Calculation of Complex Concentrations Arising from Side Reactions and Its Applications. University Chemistry, 2024, 39(4): 382-386. doi: 10.3866/PKU.DXHX202310043
15. [15]
  Keweiyang Zhang , Zihan Fan , Liyuan Xiao , Haitao Long , Jing Jing . Unveiling Crystal Field Theory: Preparation, Characterization, and Performance Assessment of Nickel Macrocyclic Complexes. University Chemistry, 2024, 39(5): 163-171. doi: 10.3866/PKU.DXHX202310084
16. [16]
  Tianyun Chen , Ruilin Xiao , Xinsheng Gu , Yunyi Shao , Qiujun Lu . Synthesis, Crystal Structure, and Mechanoluminescence Properties of Lanthanide-Based Organometallic Complexes. University Chemistry, 2024, 39(5): 363-370. doi: 10.3866/PKU.DXHX202312017
17. [17]
  Tao Cao , Fang Fang , Nianguang Li , Yinan Zhang , Qichen Zhan . Green Synthesis of p-Hydroxybenzonitrile Catalyzed by Spinach Extracts under Red-Light Irradiation: Research and Exploration of Innovative Experiments for Pharmacy Undergraduates. University Chemistry, 2024, 39(5): 63-69. doi: 10.3866/PKU.DXHX202309098
18. [18]
  Jingjing QING , Fan HE , Zhihui LIU , Shuaipeng HOU , Ya LIU , Yifan JIANG , Mengting TAN , Lifang HE , Fuxing ZHANG , Xiaoming ZHU . Synthesis, structure, and anticancer activity of two complexes of dimethylglyoxime organotin. Chinese Journal of Inorganic Chemistry, 2024, 40(7): 1301-1308. doi: 10.11862/CJIC.20240003
19. [19]
  Liang TANG , Jingfei NI , Kang XIAO , Xiangmei LIU . Synthesis and X-ray imaging application of lanthanide-organic complex-based scintillators. Chinese Journal of Inorganic Chemistry, 2024, 40(10): 1892-1902. doi: 10.11862/CJIC.20240139
20. [20]
  Jinfeng Chu , Yicheng Wang , Ji Qi , Yulin Liu , Yan Li , Lan Jin , Lei He , Yufei Song . Comprehensive Chemical Experiment Design: Convenient Preparation and Characterization of an Oxygen-Bridged Trinuclear Iron(III) Complex. University Chemistry, 2024, 39(7): 299-306. doi: 10.3866/PKU.DXHX202310105

Get Citation

PDF

XML

Metrics

PDF Downloads(0)
Abstract views(783)
HTML views(159)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142